JPRN-jRCTs071200028已完成未知
Dose setting test of insulin secretion inhibitor(DIAZOXIDE) for anti-obesity effect.
Moritake Higa0 个研究点目标入组 7 人开始时间: 2020年8月28日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 7
研究概览
简要总结
75mg of diazoxide was approved for visceral fat obesity patients without overt diabetes mellitus.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 30age old 至 < 65age old（—）
- 性别
- All
入选标准
- •1. Visiting Tomishiro Central Hospital at the Diabetes and Lifestyle Disease Center.
- •2. Written informed consent.
- •3. Waist length is more than 85cm of male or 90cm of female.
排除标准
- •Diabetes mellitus. Pt of Heart, Lung, Liver, Kidney or GI disease. Subjects of pregnancy or of allergy against diazoxide.
研究者
相似试验
已完成
2 期
Diazoxide-Mediated Insulin Suppression in Hyperinsulinemic Obese MenHyperinsulinismObesityNCT00151684Rijnstate Hospital25
撤回
4 期
Insulin Pre-treatment for Steroid-associated Hyperglycemia in Pregnant Diabetic PatientsHyperglycemia in Pregnant Diabetic PatientsNCT01875107University of Minnesota
进行中（未招募）
不适用
A randomized clinical trial of AdiPOse-derived stem ceLLs in the treatment of patients with ST elevation myOcardial infarction – The APOLLO Trial - Apollopatients with ST-elevation myocardial infarctionEUCTR2007-000339-24-NLCytori Therapeutics, Inc48
已完成
1 期
Glycemic Effect of Diazoxide in NAFLDNon-Alcoholic Fatty Liver DiseasePrediabetic StateInsulin ResistanceHyperinsulinemiaNCT05729282Columbia University24
进行中（未招募）
1 期
Dasiglucagon for Prevention of Low Blood Glucose Levels in People with Type 1 DiabetesType 1 diabetesMedDRA version: 21.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2020-000551-12-DKSteno Diabetes Center Copenhagen20